Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
This study involves an investigational drug called pazopanib in combination with the
chemotherapy drug vinorelbine. An investigational drug is a drug that has not been approved
by the U.S. Food and Drug Administration (FDA) for use in the United States. Vinorelbine has
been FDA approved to treat patients with NSCLC and breast cancer. Pazopanib is a vascular
endothelial growth factor inhibitor, which means it may prevent the tumor from growing its
own blood vessels thereby interfering with the growth of the tumor. Participants in this
study will be assigned to one of three groups with each group receiving a higher dose of
vinorelbine and pazopanib than the previous group. Vinorelbine will be given through a
needle in the vein on days 1 and 8 of each 21 day study treatment cycle. Pazopanib is a pill
which will be taken by mouth every day during the 21 day study treatment cycle.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose (MTD), and the recommended Phase II dose to be used in patients with metastatic NSCLC and breast cancer.
at study completion (estimated at 2 years)
Yes
Jyoti D Patel, MD
Principal Investigator
Northwestern University
United States: Food and Drug Administration
NU 09L1
NCT01060514
February 2010
February 2015
Name | Location |
---|---|
Northwestern University, Northwestern Medical Faculty Foundation | Chicago, Illinois 60611-3013 |